Abstract
Kabuki syndrome (KS) is often associated with autoimmune abnormalities, such as idiopathic thrombocytopenic purpura (ITP), autoimmune hemolytic anemia, leukoplakia and thyroiditis, as well as congenital anomalies. We herein present a KS patient with refractory ITP who achieved durable and complete remission in response to a total of four once-monthly infusions of rituximab. KS patients are often more susceptible to infection, so splenectomy should be avoided. Therefore, rituximab therapy is an alternative option for KS patients with ITP who fail to respond to first-line therapy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Niikawa N, Matsuura N, Fukushima Y, et al. Kabuki make-up syndrome: a syndrome of mental retardation, unusual faces, large end protruding ears, and postnatal growth deficiency. J Pediatr. 1981;99:565–9.
Kuroki Y, Suzuki Y, Chyo H, et al. A new malformation syndrome of long palpebral fissures, large ears, depressed nasal tip, and skeletal anomalies associated with postnatal dwarfism and mental retardation. J Pediatr. 1981;99:570–3.
Niikawa N, Kuroki Y, Kajii T, et al. Kabuki make-up (Niikawa–Kuroki) syndrome: a study of 62 patients. Am J Med Genet. 1988;31:565–89.
Kawame H, Hannibal MC, Hudgins L, et al. Phenotypic spectrum and management issues in Kabuki syndromes. J Pediatr. 1999;134:480–5.
Hoffman JD, Ciprero KL, Sullivan KE, et al. Immune abnormalities are a frequent manifestation of Kabuki syndrome. Am J Med Genet. 2005;135A:278–81.
Ming JE, Russell KL, McDonald-McGinn DM, et al. Autoimmune disorders in Kabuki syndrome. Am J Med Genet. 2005;132A:260–2.
Stasi R, Pagano A, Stipa E, et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood. 2001;98:952–7.
Bennett CM, Rogers ZR, Kinnamon DD, et al. Prospective phase 1/2 study of rituximab in children and adolescent chronic immune thrombocytopenic purpura. Blood. 2006;107:2639–42.
Wang J, Wiley JM, Luddy R, et al. Chronic immune thrombocytopenic purpura in children: assessment of rituximab treatment. J Pediatr. 2005;146:217–21.
Zaja F, Battista ML, Pirrotta MT, et al. Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura. Hematologica. 2008;93:930–3.
Provan D, Butler T, Evangelista ML, et al. Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults. Haemotologica. 2007;92:1695–8.
Stasi R, Stipa E, Forte V, et al. Variable patterns of response to rituximab treatment in adults with chronic idiopathic thrombocytopenic purpura. Blood. 2002;99:3872–3.
Taylor RP, Lindorfer MA. Drug insight: the mechanism of action of rituximab in autoimmune disease: the immune complex decoy hypothesis. Nat Clin Pract Rheumatol. 2007;3:86–95.
Olsson B, Andersson PO, Jernås M, et al. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med. 2003;9:1123–4.
Tokunaga M, Fujii K, Saito K, et al. Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab. Rheumatology. 2005;44:176–82.
Stasi R, Del Poeta G, Stipa E, et al. Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood. 2007;110:2924–30.
Acknowledgments
Conflict of interest statement
Source of funding and conflict of interest: none
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Torii, Y., Yagasaki, H., Tanaka, H. et al. Successful treatment with rituximab of refractory idiopathic thrombocytopenic purpura in a patient with Kabuki syndrome. Int J Hematol 90, 174–176 (2009). https://doi.org/10.1007/s12185-009-0387-1
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12185-009-0387-1